Uploaded May 2022 | Updated November 2026, 2 days ago
SIGNIFICANT EVENT OF THE YEAR
FDA EMERGENCY USE AUTHORIZATION OF MOLNUPIRAVIR
GREGORY BLUEMLING, PHD; GEORGE PAINTER III, PHD; MICHAEL NATCHUS, PHD; DAVID GUTHRIE, PHD; DAVID PERRYMAN, JD
Throughout the COVID-19 pandemic, there has been an incredibly large strain across the globe. Molnupiravir, an antiviral therapeutic against certain RNA viruses, was invented at Emory through the Drug Innovation Ventures at Emory (DRIVE). The therapeutic was sub-licensed to Ridgeback Biotherapeutics in 2020. It was found that molnupiravir could treat mild-to-moderate COVID-19 infections in those that are at a high risk for hospitalization or death, with the ultimate goal of keeping COVID-19 patients out of the hospital. On December 23, 2021, the U.S. Food and Drug Administration granted Emergency Use Authorization of molnupiravir for the treatment of COVID-19.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html
SIGNIFICANT EVENT OF THE YEAR
FDA EMERGENCY USE AUTHORIZATION OF MOLNUPIRAVIR
GREGORY BLUEMLING, PHD; GEORGE PAINTER III, PHD; MICHAEL NATCHUS, PHD; DAVID GUTHRIE, PHD; DAVID PERRYMAN, JD
Throughout the COVID-19 pandemic, there has been an incredibly large strain across the globe. Molnupiravir, an antiviral therapeutic against certain RNA viruses, was invented at Emory through the Drug Innovation Ventures at Emory (DRIVE). The therapeutic was sub-licensed to Ridgeback Biotherapeutics in 2020. It was found that molnupiravir could treat mild-to-moderate COVID-19 infections in those that are at a high risk for hospitalization or death, with the ultimate goal of keeping COVID-19 patients out of the hospital. On December 23, 2021, the U.S. Food and Drug Administration granted Emergency Use Authorization of molnupiravir for the treatment of COVID-19.
More information: https://www.ott.emory.edu/about/annual-celebrations/index.html






![From Social Death, Laboratory Life: Race, Diabetes, and the Science of Inclusion
In this talk, James Doucet-Battle of the University of California, Santa Cruz, draws from his recent book, Sweetness in the Blood: Race, Risk, and Type 2 Diabetes (Minnesota, 2021), to highlight the bioethical intersections of race and gender in Type 2 diabetes research recruitment. Through the raced and gendered lens of HeLa and the case of Henrietta Lacks, Doucet-Battle links HeLas salience to diabetes research with its problematic relevance to contemporary genomic science. Framing this discussion within a larger historical interrogation of the social death (Patterson) of slavery and its afterlives (Hartman), Doucet-Battle outlines his current project that counterpoises the research desire to gather sub-Saharan genomic diversity with ethno-nationalist resistance to diversity as a sociopolitical project. [September 12, 2022]
The James Weldon Johnson Institute for the Study of Race and Difference supports research, teaching, and public dialogue that examine race and intersecting dimensions of human difference including but not limited to class, gender, religion, and sexuality.
http://www.jamesweldonjohnson.emory.edu From Social Death, Laboratory Life: Race, Diabetes, and the Science of Inclusion](https://i.ytimg.com/vi/M3HuVSTXq1I/mqdefault.jpg)



